- Home
- GRNT vs XERS Comparison
GRNT vs XERS Comparison
Compare GRNT & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRNT
- XERS
- Stock Information
- Founded
- GRNT 2013
- XERS 2005
- Country
- GRNT United States
- XERS United States
- Employees
- GRNT N/A
- XERS N/A
- Industry
- GRNT Blank Checks
- XERS Biotechnology: Pharmaceutical Preparations
- Sector
- GRNT Finance
- XERS Health Care
- Exchange
- GRNT Nasdaq
- XERS Nasdaq
- Market Cap
- GRNT 793.2M
- XERS 752.7M
- IPO Year
- GRNT N/A
- XERS 2018
- Fundamental
- Price
- GRNT $5.73
- XERS $7.75
- Analyst Decision
- GRNT Buy
- XERS Strong Buy
- Analyst Count
- GRNT 2
- XERS 7
- Target Price
- GRNT $7.50
- XERS $6.79
- AVG Volume (30 Days)
- GRNT 600.1K
- XERS 3.4M
- Earning Date
- GRNT 08-07-2025
- XERS 08-07-2025
- Dividend Yield
- GRNT 7.68%
- XERS N/A
- EPS Growth
- GRNT N/A
- XERS N/A
- EPS
- GRNT 0.25
- XERS N/A
- Revenue
- GRNT $409,332,000.00
- XERS $246,025,000.00
- Revenue This Year
- GRNT $32.19
- XERS $35.31
- Revenue Next Year
- GRNT $14.74
- XERS $19.65
- P/E Ratio
- GRNT $23.30
- XERS N/A
- Revenue Growth
- GRNT 10.32
- XERS 35.62
- 52 Week Low
- GRNT $4.52
- XERS $2.48
- 52 Week High
- GRNT $7.00
- XERS $7.79
- Technical
- Relative Strength Index (RSI)
- GRNT 62.42
- XERS 80.09
- Support Level
- GRNT $5.17
- XERS $7.27
- Resistance Level
- GRNT $5.53
- XERS $7.79
- Average True Range (ATR)
- GRNT 0.20
- XERS 0.41
- MACD
- GRNT 0.08
- XERS 0.08
- Stochastic Oscillator
- GRNT 96.52
- XERS 98.43
About GRNT Granite Ridge Resources Inc.
Granite Ridge Resources Inc is a scaled, non-operated oil and gas exploration and production company. It invests in a diversified portfolio of production and top-tier acreage across the Permian and other prolific U.S. basins in partnership with operators. It generates maximum revenue from Oil.
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).